Tens of thousands!!!And our stock is at 0.43 cents and people are shy to own this stock... lol....
To me it a no brainner and is definatley worth the risk reward ratio for me.
"US patent No. 9,345,769 provides patent protection for tens of thousands of metal based photodynamic compounds (PDCs); including, Theralase's TLD-1433, currently under investigation by the company for the destruction of non-muscle invasive bladder cancer (NMIBC)." "Under worldwide exclusive licence agreement with the inventor of the latest patent, Dr. Sherri McFarland has agreed to maintain strict confidentiality on any trade secrets associated with the synthesis or manufacture of TLD-1433 for a period of 20 additional years following the expiry of the last patent covering inventions or improvements in compounds or their methods of use, thereby increasing minimum proprietary protection of TLD-1433 in the US until June 22, 2054." https://www.proactiveinvestors.com/companies/news/127316/theralase-receives-us-patent-for-tld-1433-drug-127316.html
https://theralase.com/pressrelease/theralase-granted-us-patent-lead-anti-cancer-drug-2/
And then this....
"The USPTO granted U.S. Patent Number 9,676,806 B2 entitled, “Metal-Based Thiophene Photodynamic Compounds and Their Use”, which issued on June 13, 2017, as a continuation of U.S. Patent No. 9,345,769" https://theralase.com/pressrelease/theralase-researcher-granted-second-us-patent-for-novel-anti-cancer-drugs/
"This milestone demonstrates Theralase’s ability to consistently and reliably manufacture its lead light activated drug in the same purity and yield as the original GMP batch." Does this mean they can produce in house? I think so...
https://theralase.com/pressrelease/theralase-completes-gmp-manufacture-of-second-batch-of-lead-drug/
Also...
"Theralase Completes GMP Manufacture of Lead Drug Toronto, Ontario – September 8, 2015, Theralase Technologies Inc. (“Theralase” or the “Company”) (TLT:TSXV) (TLTFF:OTC), a leading biotechnology manufacturer focused on commercializing medical technologies to eliminate pain and destroy cancer, announced today that it has completed manufacture of its lead Photo Dynamic Compound (“PDC”), TLD-1433 in compliance with Good Manufacturing Practice (“GMP”) standards. This milestone is critical for a Clinical Trial Application (“CTA”) submission to Health Canada.
Pending Health Canada approval of the CTA, Theralase would commence enrolling patients inflicted with Non-Muscle Invasive Bladder Cancer (“NMIBC”) into a Phase Ib clinical trial aimed at proving the primary objective of safety and tolerability with an exploratory objective of efficacy.
Completion of the GMP manufacturing of TLD-1433 is a major milestone for the Company and is a prerequisite for a CTA application. Supporting data includes a Chemistry, Manufacturing, and Control (“CMC”) analysis detailing pertinent specifications of the drug" https://theralase.com/pressrelease/theralase-completes-gmp-manufacture-of-lead-drug/
Who produces TLD initially? Sigma Aldridge Fine Chemicals (“
SAFC”) 2015
"Roger Dumoulin-White, President and CEO stated, “CiToxLAB is a strategic partner that completes the last missing piece in our Health Canada Clinical Trial Application (“CTA”); specifically, a detailed toxicology analysis of TLD-1433, for final submission to Health Canada regulatory officials this summer. Previously announced strategic partners include: Sigma Aldridge Fine Chemicals (“SAFC”), a division of Sigma Aldridge, to manufacture TLD-1433 and JSS Medical Research Inc. to provide regulatory monitoring of our clinical trials and to assist in our interactions with Health Canada and the Food and Drug Administration (“FDA”).”
https://theralase.com/pressrelease/theralase-partners-with-citoxlab-for-toxicology/
Sigma Aldridge Fine Chemicals is now Millipore Sigma. https://www.sigmaaldrich.com/canada-english.html
MilliporeSigma is the life science business of Merck KGaA of Darmstadt, Germany - the worlds oldest pharmaceutical and chemical company. https://www.emdmillipore.com/CA/en/about-us/FYib.qB.IAYAAAE_0T93.L6m,nav?ReferrerURL=https%3A%2F%2Fwww.google.ca%2F